包装 | 价格(元) |
10mM (in 1mL DMSO) | 电议 |
5mg | 电议 |
25mg | 电议 |
Target | Human LDHs (LDH1 and LDH5) |
Preparation method | The solubility of this compound in DMSO is >8.8mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 500 μM |
Applications | Isosafrole strongly inhibited the pyruvate-to-lactate conversion by both LDH1 and LDH5, suggesting that it inhibited lactate production itself. |
Animal models | Kainate mice model |
Dosage form | 100 to 300 mg/kg; intraperitoneal injection |
Application | In the hippocampus of mice 2 weeks after the kainate injection, Isosafrole (200 to 300 mg/kg) strongly suppressed spontaneous high-voltage spikes and paroxysmal discharges. Isosafrole was an LDH inhibitor that suppressed seizures in vivo. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
产品描述 | Isosafrole, a stiripentol analog, is a potent LDH inhibitor. Stiripentol is a new-generation antiepileptic drug, and its chemical structure is unrelated to other antiepileptic drugs. Seizures and epileptiform activity are reduced by inhibition of the metabolic pathway via lactate dehydrogenase (LDH), which is a component of the astrocyte-neuron lactate shuttle. |